GlassScriptPhysician profile
Laura Tarabocchia
NPI 1528210762
$3,209.71
in general payments reported to CMS, 2019-2025
31 companies · $552 in 2025
The $552 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $809 · 2022: $698 · 2023: $366 · 2024: $784 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,702.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $849.99 | 2021-2025 | |
| Lilly USA, LLC | $387.55 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Dexcom, INC. | $310.15 | 2021-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $292.29 | 2021-2022 | |
| Astellas Pharma US INC | $121.25 | 2023-2025 | Veozah |
| Amgen INC. | $120.91 | 2024-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $120.84 | 2021-2024 | Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $103.19 | 2021-2024 | Airsupra, Breztri, Farxiga |
| Sanofi-Aventis U.S. LLC | $87.46 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.18 | 2021-2024 | Jardiance |
| Novo Nordisk INC | $66.72 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $58.20 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.07 | 2021-2024 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $52.00 | 2021 | |
| Inspire Medical Systems, INC. | $51.60 | 2025 | Inspire |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $51.10 | 2025 | Yupelri |
| Esperion Therapeutics, INC. | $48.47 | 2021-2022 | |
| Medtronic, INC. | $47.98 | 2023-2024 | Venaseal, Corevalve Evolut R, Vanta Adaptivestim |
| Merck Sharp & Dohme LLC | $47.61 | 2021-2022 | |
| Vivus LLC | $40.32 | 2022 | |
| Jazz Pharmaceuticals INC. | $36.11 | 2021-2022 | |
| Mylan Specialty L.P. | $24.34 | 2024 | Yupelri |
| Abbott Laboratories | $22.82 | 2023 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $22.73 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.88 | 2021 | |
| Corcept Therapeutics | $20.72 | 2024 | Korlym |
| Impel Pharmaceuticals INC. | $20.15 | 2023 | Trudhesa |
| Ironwood Pharmaceuticals, INC | $19.69 | 2023 | Linzess |
| Eisai INC. | $12.30 | 2021 | |
| Antares Pharma, INC. | $12.23 | 2021 | |
| Echosens North America, INC. | $10.86 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Tarabocchia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.